We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Synthetic Estrogen-Progestin Combinations Effect on Hormone-sensitive Breast Cancer in the Rat

E. Douglas McSweeney Jr., MD; William S. Fletcher, MD
Arch Surg. 1969;99(5):652-654. doi:10.1001/archsurg.1969.01340170104025.
Text Size: A A A
Published online


Recently Huggins et al1 described a hormone-sensitive breast carcinoma in the Sprague-Dawley rat induced by one feeding of the carcinogen—7,12-dimethylbenz- [α]anthracene (DMBA). Using this induced tumor it has been shown in this laboratory that it is possible to extinguish hormone-sensitive tumors in the rat with 10μc of diethylstilbestrol diphosphate tagged with radioactive phosphorous (32P). The tumor uptake of 32P is doubled by its incorporation into the diethylstilbestrol molecule.2 The dramatic response of these tumors to diethylstilbestrol and 32P-tagged diethylstilbestrol diphosphate, as well as the fact that Huggins has reported similar tumors to be extinguished by a mixture of estradiol 17-β and progesterone,3 led us to study the effect of various other commonly used synthetic female hormones. The following substances were tested: (1) the synthetic progestin-estrogen combination of norethynodrel with mestranol (Enovid), (2) the synthetic progestin, norethynodrel, and (3) the synthetic estrogen, diethylstilbestrol. The chemical


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.